AQHA Announces Medication Updates for Cetirizine and Acetazolamide

The American Quarter Horse Association has announced updates regarding the use of cetirizine and acetazolamide in AQHA competition. Effective immediately, cetirizine will be a permitted substance, and an acetazolamide therapeutic use exemption (TUE) is available for horses with qualifying medical conditions requiring continuous treatment.

Cetirizine approved as a Permitted Substance

Cetirizine may now be used in horses competing in AQHA competition without requiring competitors to file a medication report form (MRF). Cetirizine is a second-generation antihistamine routinely used in horses to help reduce allergic skin reactions and other seasonal allergy symptoms. Previously treated as a conditionally permitted medication, cetirizine required an MRF to be filed when administered. With its classification as a permitted substance, that reporting requirement no longer applies.

Acetazolamide Therapeutic Use Exemption

AQHA also offers an acetazolamide therapeutic use exemption for horses requiring continuous acetazolamide treatment for a substantiated myopathy, or disease of the muscle tissue, at the recommendation of a veterinarian.

The TUE allows an eligible horse to continue treatment with acetazolamide without withdrawing the medication 24 hours before competition.

To apply for an acetazolamide TUE, the owner or trainer must complete an online medication report form and indicate that they would like the horse to be considered for an acetazolamide therapeutic use exemption. Veterinary documentation, including biopsy and bloodwork, supporting the necessity of continuous therapy is required as part of the TUE process.

If a horse has tested DNA-positive for hyperkalemic periodic paralysis or has an approved acetazolamide TUE, the horse may remain on acetazolamide without withdrawing the medication prior to competition. Once approved, an MRF does not need to be filed each time the horse competes while receiving acetazolamide.

An approved acetazolamide TUE does not need to be renewed.

Owners, trainers and veterinarians can complete the acetazolamide therapeutic use exemption veterinarian form here.

AQHA encourages exhibitors and veterinarians to familiarize themselves with the Association’s current medication rules and requirements before competition.

For additional information regarding AQHA medications and prohibited substances, visit AQHA.com.